A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1

Summary

This is a multi-center, single-arm, open label, non-randomized, phase II study designed to investigate the efficacy, safety and tolerability of obinutuzumab given as monotherapy in patients with relapsed/refractory Waldenström Macroglobulinemia (R/R MW).

Timeline

Start

2018-09-21

Primary completion

2019-04

Completion

2022-12

Publications

• Wrobel T, Kalicinska E, Zaucha JM, Morawska M, Giannopoulos K, Jamroziak K, Lech-Maranda E, Taszner M, Szeremet A, Malecki B, Druzd-Sitek A, Lojko-Dankowska A, Dytfeld D. Obinutuzumab induction and maintenance in patients with Waldenstrom macroglobulinaemia: an open-label, single-arm phase 2 study. EClinicalMedicine. 2025 Jul 25;86:103383. doi: 10.1016/j.eclinm.2025.103383. eCollection 2025 Aug.

Drugs

Indications